TN2009000095A1 - Thiazole pyrazolopyrimidines as crf1 receptor antagonists - Google Patents

Thiazole pyrazolopyrimidines as crf1 receptor antagonists

Info

Publication number: TN2009000095A1
Authority: TN; Tunisia
Prior art keywords: receptor antagonists; crf1 receptor; pyrazolopyrimidines; thiazole; thiazole pyrazolopyrimidines
Prior art date: 2006-09-20

Application number

TN2009000095A

Other languages

English (en)

Inventor

Zhaogen Chen

Chafiq Hamdouchi Hamdouchi

Erik James Hembre

Philip Arthur Hipskind

Jason Kenneth Myers

Takako Takakuwa

James Lee Toth

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-20

Filing date

2009-03-19

Publication date

2010-08-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38924802&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000095(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-03-19 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2010-08-19 Publication of TN2009000095A1 publication Critical patent/TN2009000095A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Reproductive Health (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Child & Adolescent Psychology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Anesthesiology (AREA)
Immunology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

TN2009000095A 2006-09-20 2009-03-19 Thiazole pyrazolopyrimidines as crf1 receptor antagonists TN2009000095A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US82626406P	2006-09-20	2006-09-20
PCT/US2007/078605 WO2008036579A1 (fr)	2006-09-20	2007-09-17	Thiazole pyrazolopyrimidines convenant comme antagonistes du récepteur du crf1

Publications (1)

Publication Number	Publication Date
TN2009000095A1 true TN2009000095A1 (en)	2010-08-19

Family

ID=38924802

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TN2009000095A TN2009000095A1 (en)	2006-09-20	2009-03-19	Thiazole pyrazolopyrimidines as crf1 receptor antagonists

Country Status (33)

Country	Link
US (1)	US8030304B2 (fr)
EP (1)	EP2094709B1 (fr)
JP (1)	JP5161226B2 (fr)
KR (1)	KR101088239B1 (fr)
CN (1)	CN101516887B (fr)
AR (1)	AR062886A1 (fr)
AT (1)	ATE481405T1 (fr)
AU (1)	AU2007297421B2 (fr)
BR (1)	BRPI0717023B8 (fr)
CA (1)	CA2663511C (fr)
CL (1)	CL2007002693A1 (fr)
CR (1)	CR10682A (fr)
CY (1)	CY1110854T1 (fr)
DE (1)	DE602007009305D1 (fr)
DK (1)	DK2094709T3 (fr)
EA (1)	EA015179B1 (fr)
ES (1)	ES2350282T3 (fr)
HR (1)	HRP20100516T1 (fr)
IL (1)	IL197614A (fr)
MA (1)	MA30798B1 (fr)
MX (1)	MX2009003125A (fr)
MY (1)	MY146388A (fr)
NO (1)	NO20091489L (fr)
NZ (1)	NZ575572A (fr)
PE (1)	PE20081377A1 (fr)
PL (1)	PL2094709T3 (fr)
PT (1)	PT2094709E (fr)
RS (1)	RS51545B (fr)
SI (1)	SI2094709T1 (fr)
TN (1)	TN2009000095A1 (fr)
TW (1)	TWI402269B (fr)
UA (1)	UA96458C2 (fr)
WO (1)	WO2008036579A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2025674A1 (fr)	2007-08-15	2009-02-18	sanofi-aventis	Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
AU2009298757B2 (en) *	2008-10-02	2013-08-01	Eli Lilly And Company	Thiazolyl-pyrazolopyrimidine compounds as synthetic intermediates and related synthetic processes
EP2567959B1 (fr)	2011-09-12	2014-04-16	Sanofi	Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
NZ722122A (en) *	2014-01-21	2020-06-26	Neurocrine Biosciences Inc	Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia
PL236355B1 (pl) *	2015-04-02	2021-01-11	Celon Pharma Spolka Akcyjna	Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
WO2018048953A1 (fr)	2016-09-07	2018-03-15	The Regents Of The University Of California	Antagonistes allostériques du récepteur 1 du facteur de libération de la corticotropine (crfr1) qui diminuent la p-tau et améliorent la cognition
AU2018317398A1 (en)	2017-08-14	2019-11-21	Spruce Biosciences, Inc.	Corticotropin releasing factor receptor antagonists
AU2018318990B2 (en) *	2017-08-14	2023-01-05	Spruce Biosciences, Inc.	Corticotropin releasing factor receptor antagonists
BR112020024062A2 (pt) *	2018-04-27	2021-02-09	Spruce Biosciences, Inc.	métodos para o tratamento de tumores de restos adrenais de testículo e de ovário
CN109134481B (zh) *	2018-08-07	2021-05-14	中山大学	一种取代吡咯色原酮类化合物或其药学上可接受的盐及其制备方法和应用
TWI714231B (zh) *	2018-09-04	2020-12-21	美商美國禮來大藥廠	2,6-二胺基吡啶化合物
AU2019393256B2 (en)	2018-12-07	2025-07-31	Neurocrine Biosciences, Inc.	CRF1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
BR112022000956A2 (pt) *	2019-07-19	2022-04-05	Spruce Biosciences Inc	Métodos de tratamento da hiperplasia adrenal congênita
CN118252829A (zh)	2019-09-27	2024-06-28	纽罗克里生物科学有限公司	Crf受体拮抗剂及使用方法
US20230065034A1 (en) *	2019-12-04	2023-03-02	Neurocrine Biosciences, Inc.	Crf receptor antagonists and methods of use
GR1010096B (el) *	2020-07-02	2021-10-08	Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε,	Πυραζολο[1,5-a]πυριμιδινες με δραση αναστολης της αυτοταξινης
JP2023537598A (ja) *	2020-08-12	2023-09-04	スプルースバイオサイエンシーズ，インク．	多嚢胞性卵巣症候群を処置するための方法および組成物
US20240024330A1 (en)	2020-08-26	2024-01-25	Neurocrine Biosciences, Inc.	Crf receptor antagonists and methods of use
WO2022197798A1 (fr)	2021-03-19	2022-09-22	Crinetics Pharmaceuticals, Inc.	Antagoniste du récepteur du sous-type 2 de la mélanocortine (mc2r) pour le traitement d'une maladie
US11708372B2 (en)	2021-11-19	2023-07-25	Spruce Biosciences, Inc.	Crystalline composition of tildacerfont and methods of use and preparation thereof
JP2024539907A (ja) *	2021-11-19	2024-10-31	スプルースバイオサイエンシーズ，インク．	チルダセルフォントの結晶性組成物ならびにその使用方法および調製方法
WO2023163945A1 (fr) *	2022-02-23	2023-08-31	Crinetics Pharmaceuticals, Inc.	Traitement de l'hyperplasie surrénale congénitale et du syndrome des ovaires polykystiques
WO2025188842A1 (fr) *	2024-03-08	2025-09-12	Spruce Biosciences, Inc.	Dispersion solide amorphe de formulations de tildacerfont

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1994013676A1 (fr)	1992-12-17	1994-06-23	Pfizer Inc.	Pyrrolopyrimidines en tant qu'antagonistes du facteur liberateur de corticotrophine (crf)
CZ244598A3 (cs)	1996-02-07	1998-10-14	Janssen Pharmaceutica N.V.	Pyrazolopyrimidiny jako antagonisty CRF receptoru
EA006626B1 (ru) *	1996-07-24	2006-02-24	Дюпон Фармасьютикалз Компани	Азолопиримидины, фармацевтическая композиция и способ лечения
BR9710544A (pt) *	1996-07-24	1999-08-17	Du Pont Pharm Co	M-todo de tratamento composto e composi-Æo farmac-utica
WO1998008847A1 (fr)	1996-08-28	1998-03-05	Pfizer Inc.	Derives 6,5-hetero-bicycliques substitues
EP1040831A3 (fr) *	1999-04-02	2003-05-02	Pfizer Products Inc.	Utilisation d'antagonistes du facteur de libération de la corticotropine pour la prévention de la mort subite
AU4203500A (en) *	1999-04-06	2000-10-23	Du Pont Pharmaceuticals Company	Pyrazolopyrimidines as crf antagonists
DE60032249T2 (de) *	1999-09-30	2007-07-19	Neurogen Corp., Branford	Amino-substituierte Pyrazolo-[1,5-a]-1,5-Pyrimidine und Pyrazolo-[1,5-a]-1,3,5-Triazine
KR100875595B1 (ko) *	2001-03-13	2008-12-23	브리스톨-마이어스 스퀴브 파마 컴파니	코르티코트로핀 방출인자 수용체 리간드로서4-(2-부틸아미노)-2,7-디메틸-8-(2-메틸-6-메톡시피리드-3-일) 피라졸로-[1,5-에이]-1,3,5-트리아진, 그의 거울상이성질체 및 약학적으로 허용가능한 염
AR046967A1 (es)	2003-12-22	2006-01-04	Sb Pharmco Inc	Compuesto de pirazol[1,5-a]pirimidina, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion

2007
- 2007-09-17 DE DE602007009305T patent/DE602007009305D1/de active Active
- 2007-09-17 AT AT07842582T patent/ATE481405T1/de active
- 2007-09-17 WO PCT/US2007/078605 patent/WO2008036579A1/fr active Application Filing
- 2007-09-17 MX MX2009003125A patent/MX2009003125A/es active IP Right Grant
- 2007-09-17 SI SI200730435T patent/SI2094709T1/sl unknown
- 2007-09-17 BR BRPI0717023A patent/BRPI0717023B8/pt active IP Right Grant
- 2007-09-17 RS RSP-2010/0517A patent/RS51545B/en unknown
- 2007-09-17 NZ NZ575572A patent/NZ575572A/en not_active IP Right Cessation
- 2007-09-17 US US12/377,733 patent/US8030304B2/en active Active
- 2007-09-17 AU AU2007297421A patent/AU2007297421B2/en not_active Ceased
- 2007-09-17 EP EP07842582A patent/EP2094709B1/fr active Active
- 2007-09-17 CN CN2007800351453A patent/CN101516887B/zh active Active
- 2007-09-17 PT PT07842582T patent/PT2094709E/pt unknown
- 2007-09-17 UA UAA200902216A patent/UA96458C2/ru unknown
- 2007-09-17 JP JP2009529316A patent/JP5161226B2/ja active Active
- 2007-09-17 EA EA200970303A patent/EA015179B1/ru active IP Right Revival
- 2007-09-17 HR HR20100516T patent/HRP20100516T1/hr unknown
- 2007-09-17 PL PL07842582T patent/PL2094709T3/pl unknown
- 2007-09-17 DK DK07842582.4T patent/DK2094709T3/da active
- 2007-09-17 MY MYPI20091067A patent/MY146388A/en unknown
- 2007-09-17 ES ES07842582T patent/ES2350282T3/es active Active
- 2007-09-17 KR KR1020097005602A patent/KR101088239B1/ko not_active Expired - Fee Related
- 2007-09-17 CA CA2663511A patent/CA2663511C/fr active Active
- 2007-09-18 AR ARP070104125A patent/AR062886A1/es active IP Right Grant
- 2007-09-20 CL CL200702693A patent/CL2007002693A1/es unknown
- 2007-09-20 PE PE2007001271A patent/PE20081377A1/es not_active Application Discontinuation
- 2007-09-20 TW TW096135177A patent/TWI402269B/zh not_active IP Right Cessation
2009
- 2009-03-16 IL IL197614A patent/IL197614A/en active IP Right Grant
- 2009-03-19 TN TN2009000095A patent/TN2009000095A1/fr unknown
- 2009-03-20 CR CR10682A patent/CR10682A/es not_active Application Discontinuation
- 2009-04-16 NO NO20091489A patent/NO20091489L/no not_active Application Discontinuation
- 2009-04-16 MA MA31794A patent/MA30798B1/fr unknown
2010
- 2010-10-21 CY CY20101100946T patent/CY1110854T1/el unknown

Also Published As

Publication number	Publication date
KR20090052366A (ko)	2009-05-25
DK2094709T3 (da)	2010-12-06
EA015179B1 (ru)	2011-06-30
BRPI0717023B8 (pt)	2021-05-25
PT2094709E (pt)	2010-10-04
IL197614A0 (en)	2009-12-24
BRPI0717023A2 (pt)	2014-03-11
JP2010504344A (ja)	2010-02-12
KR101088239B1 (ko)	2011-11-30
CN101516887B (zh)	2011-11-02
RS51545B (en)	2011-06-30
CA2663511A1 (fr)	2008-03-27
SI2094709T1 (sl)	2011-01-31
HRP20100516T1 (hr)	2010-10-31
JP5161226B2 (ja)	2013-03-13
PE20081377A1 (es)	2008-09-18
MY146388A (en)	2012-08-15
AU2007297421A1 (en)	2008-03-27
HK1132505A1 (en)	2010-02-26
US20100222339A1 (en)	2010-09-02
WO2008036579A1 (fr)	2008-03-27
TW200821312A (en)	2008-05-16
NZ575572A (en)	2011-10-28
CR10682A (es)	2009-08-13
UA96458C2 (ru)	2011-11-10
EA200970303A1 (ru)	2009-10-30
BRPI0717023B1 (pt)	2019-11-19
ATE481405T1 (de)	2010-10-15
DE602007009305D1 (de)	2010-10-28
EP2094709A1 (fr)	2009-09-02
CL2007002693A1 (es)	2008-04-18
AU2007297421B2 (en)	2012-03-08
CN101516887A (zh)	2009-08-26
IL197614A (en)	2012-10-31
ES2350282T3 (es)	2011-01-20
CY1110854T1 (el)	2015-06-10
MA30798B1 (fr)	2009-10-01
CA2663511C (fr)	2012-12-04
PL2094709T3 (pl)	2011-02-28
US8030304B2 (en)	2011-10-04
MX2009003125A (es)	2009-05-28
TWI402269B (zh)	2013-07-21
EP2094709B1 (fr)	2010-09-15
NO20091489L (no)	2009-04-16
AR062886A1 (es)	2008-12-10

Publication	Publication Date	Title
TN2009000095A1 (en)	2010-08-19	Thiazole pyrazolopyrimidines as crf1 receptor antagonists
MX2009003098A (es)	2009-04-01	Compuestos de tiofen pirazolopirimidina.
CY1109069T1 (el)	2014-07-02	Ενωσεις ιμιδαζοπυριδαζινης
GB0625648D0 (en)	2007-01-31	Compounds
MX2010013020A (es)	2011-03-21	Metodos y composiciones para trastornos del sueño y otros trastornos.
DK1951729T3 (da)	2014-10-06	Oxygenbundne pyrimidinderivater
MX2009006704A (es)	2009-06-30	Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
EA200602062A1 (ru)	2007-04-27	Амидосоединения и их применение в качестве фармацевтических средств
SG170828A1 (en)	2011-05-30	Deazapurines useful as inhibitors of janus kinases
ZA201100526B (en)	2012-04-25	Triazolo [4,5-d]pyramidine derivatives and their use as purine receptor antagonists
WO2008045564A3 (fr)	2008-05-29	Composés de carboxamide et leur utilisation
MX2009010127A (es)	2009-11-05	Compuestos utiles como inhibidores de janus cinasas.
GEP20135927B (en)	2013-10-10	1-benzyl-3-hydroxymethylindaz-ole derivatives and usage thereat treatment of diseases based on mcp-1, cx3cr1 and p40 expression
CL2007000789A1 (es)	2008-01-18	Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
DE602007007934D1 (en)	2010-09-02	Imidazoazephinonverbindungen
WO2006138589A3 (fr)	2009-04-16	Ligands de recepteur opioide
WO2005094798A3 (fr)	2006-04-13	Compositions pharmaceutiques a base d'anticholinergiques et d'antagonistes du recepteur ccr2